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Abstract
Introduction: Multiple system atrophy is a late, adult-onset a-synucleinopathy with no data on the effect of
pregnancy on the disease course. Early stage multiple system atrophy can be difficult to distinguish from
Parkinson’s disease.
Case presentation: We describe the case of an Irish woman with parkinsonism starting at age 31, initially
diagnosed as having dopa-responsive, idiopathic Parkinson’s disease, who successfully delivered a full-term child at
age 35. Her pregnancy was complicated by severe orthostatic hypotension and motor fluctuations. Two years post-
partum, she underwent bilateral subthalamic nuclei deep brain stimulation for intractable motor fluctuations and
disabling dyskinesia. After this treatment course she experienced deterioration of motor symptoms and death eight
years after disease onset. Post-mortem neuropathological examination revealed striatonigral degeneration and a-
synuclein-positive glial cytoplasmic inclusions in brain stem nuclei, basal ganglia and white matter tracts, consistent
with a neuropathological diagnosis of multiple system atrophy.
Conclusions: Multiple system atrophy can affect women of child-bearing age and pregnancy may be associated
with marked disease progression.
Introduction
Multiple system atrophy (MSA) is an a-synucleinopathy
characterized by akinetic-rigid parkinsonism, autonomic
failure, urogenital dysfunction, cerebellar signs, and pyra-
midal signs in varying combinations [1]. Based on motor
presentation, MSA can be classified into two separate but
overlapping clinical subtypes: MSA with predominant par-
kinsonism (MSA-P) and MSA with predominant cerebel-
lar ataxia (MSA-C) [1,2]. Motor features of MSA-P
include akinesia/bradykinesia, rigidity, postural instability,
and tremor. As many as one-third of patients with MSA-P
have rest tremor [3]. According to the 2008 MSA consen-
sus statement, poor levodopa-responsiveness parkinsonism
is considered one of the important characteristics to diag-
n o s ep r o b a b l eM S A - P[ 2 ] .H o w e v e r ,t h ee a r l ys t a g eo f
MSA-P often responds to levodopa and may have subtle
or absent autonomic dysfunction, making it difficult to
distinguish from Parkinson’s disease (PD) [4]. Confirma-
tion of the diagnosis of definite MSA-P is based on
neuropathological evidence of Papp-Lantos bodies (a-
synuclein-positive glial cytoplasmic inclusions (GCIs)) and
striatonigral degeneration [2].
According to the European MSA registry, the mean age
at onset is 57.8 years [5]. Given the late-life onset, there is
no available information on effects of gestation on the
symptoms and course of MSA. Equally important is the
effect of MSA and medication treatment on the gestation,
fetal development, delivery, lactation and ability to care for
a newborn. We describe the case of a woman with patho-
logically confirmed MSA-P who was diagnosed PD when
she became pregnant and underwent a successful preg-
nancy and delivered a full-term healthy baby.
Case presentation
A 31-year-old Irish woman who resided in the midwes-
tern USA developed progressive loss of left hand dexter-
ity and rest tremor. Eight months later, she experienced
episodes of pre-syncope triggered by going up or down
stairs or by a hot environment. Her initial neurological
examination revealed rigidity, bradykinesia, decreased left
arm swing, and rest/action tremor in the ipsilateral hand
but no pyramidal, cerebellar signs or objective orthostatic
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Scale motor subsection part III (UPDRS III) score [6] was
18 points. Results of routine blood examination, cerulo-
plasmin, and a cerebral magnetic resonance imaging
(MRI) scan were normal. She was diagnosed as having
early-onset idiopathic Parkinson’s disease, based upon
gradual onset asymmetric parkinsonism with rest tremor.
She initially declined pharmacological treatment until her
symptoms spread to her left lower extremity and right
hand one year later. She was started on a dopamine ago-
nist pramipexole 0.75 mg three times a day, with good
results.
Six months later, she and her husband decided to have a
child. We advised her and her husband that carbidopa/
levodopa had been reported to be used safely in pregnant
women with PD [7,8], but there was insufficient informa-
tion about the safety of pramipexole in pregnancy. As a
result, pramipexole was switched to levodopa/carbidopa.
She had excellent response to levodopa/carbidopa with
mild levodopa-induced dyskinesias at doses that provided
optimal motor benefit, 900 mg levodopa/day. Five months
after she started taking levodopa, her UPDRS III score
decreased from 20.5 to 11 points and she became pregnant
with her first child.
During her second month of pregnancy, she developed
syncope after arising from a supine position. She noticed
that she had less responsiveness to levodopa and her ON
state total UPDRS score was 48 points with UPDRS III
subscore of 30 points. She had marked symptomatic
orthostatic hypotension with supine blood pressure 116/
70 mmHg and standing blood pressure 70/50 mmHg. Her
motor function worsened substantially, and by pregnancy
week 30, her total UPDRS score was 56.5 points with
UPDRS III subscore of 38.5 points. The dose of levodopa
was not increased throughout her pregnancy due to
potential exacerbation of orthostatic hypotension.
At age of 35, she gave birth to a full-term 2.9 kg girl with
Apgar scores of eight at one minute and nine at five min-
utes by caesarean section, due to breech presentation.
General and neurological examination of the baby revealed
no abnormalities and the routine neonatal blood tests
were normal. She did not breastfeed her child. At age five
years, her daughter had developed normally except for
recurrent strabismus and a dermoid cyst in the anterior
neck. Given that MSA is usually considered to be a rare
and sporadic disease [1], her daughter was not followed by
a neurologist routinely.
One week after delivery, her total UPDRS score
decreased to 37 points with UPDRS III subscore of 22
points on the same levodopa dose. Her blood pressure
was 110/60 mmHg when lying and 100/62 mmHg when
standing. Despite symptom improvement in the first
post-partum month, she had subsequent worsening (with
a UPDRS score of 60.5) necessitating escalation of
levodopa. Entacapone was added after her orthostatic
hypotension was improved with midodrine. She had
good initial response, but developed marked motor fluc-
tuations with increase OFF time, peak-dose/diphasic dys-
kinesias and orthostatic hypotension, despite multiple
medication adjustments.
At age of 37, she received bilateral subthalamic nuclei
deep brain stimulation (DBS) surgery uneventfully after
an in-patient motor evaluation showing response to levo-
dopa (OFF and ON states with UPDRS III subscore 62
and 20.5, respectively). A pre-surgical brain MRI scan
revealed no atrophy or abnormal signal in the putamen
or hot cross bun sign in the pons. However, she had very
limited and transient benefit from subthalamic nuclei
deep brain stimulation (STN-DBS) therapy despite multi-
ple attempts of programming. She developed urinary
incontinence, progressive dysarthria, dysphagia, and inha-
latory/exhalatory stridor within a few months. Her dysar-
t h r i aa n dd y s p h a g i aw e r ew o r s ea f t e rt a k i n gh e r
medications, but she was still able to take food by mouth.
Within a year, she required a wheelchair, assistance with
all activities of daily living, an indwelling urinary catheter
for urinary retention, and an augmentative communica-
tion device for levodopa-induced dysarthria. Her body
mass index (BMI) was 20.5 two months prior to her
death, compared to 23 when she was diagnosed PD. All
these symptoms raised the possibility of MSA-P. Nearly
eight years into her disease course, she died in her sleep
possibly due to the laryngeal stridor.
Post-mortem macroscopic examination revealed mark-
edly depigmented substantia nigra and locus coeruleus
(Figure 1A), and mildly atrophic brainstem and cerebel-
lum. The two stimulation electrodes terminated in the
subthalamic nuclei. Microscopic examination showed
severe loss of neurons, gliosis, and extracellular pigment
in the substantia nigra (Figure 1B) and locus coeruleus;
there was also gliosis and neuronal loss in the basis pon-
tis, medulla oblongata, and cerebellum. There were
numerous a-synuclein-immunoreactive glial cytoplasmic
inclusions (GCIs), Papp-Lantos bodies [9] in the substan-
tia nigra (Figure 1C), red nucleus, crus cerebri, striatum,
pallidum, medulla oblongata, and white matter of the
frontal lobe and cerebellum. Fewer GCIs were seen in the
white matter of the temporal and parietal lobes, hippo-
campus, thalamus and subthalamic nucleus. There were
numerous GCIs, few glial intra-nuclear inclusions (GIIs),
dystrophic neurites (DNs), and scattered neuronal intra-
nuclear inclusions (NIIs) and few neuronal cytoplasmic
inclusions (NCIs) throughout the pontine nuclei (Figure
2A-C). Although there was no macroscopic atrophy
noticed in the putamen, minimal neuronal loss, mild glio-
sis and numerous a-synuclein-immunoreactive GCIs
were observed. No tau-positive pre-tangles or a-synuclein
immunoreactive Lewy bodies were seen. These
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Page 2 of 5Figure 1 (A-C) Macroscopic and microscopic features of our patient’s brain (post-mortem). (A) Left: hemi-midbrain showing pallor of the
substantia nigra (between arrows); right: control midbrain showing normal pigmentation. (B) Severe neuronal loss, microvacuolation, and gliosis
in the substantia nigra of affected hemi-midbrain. Macrophages containing neuromelanin pigment (arrows). (C) Numerous glial cytoplasmic
inclusions in the internal capsule. Stain types: (B), hematoxylin and eosin; (C), a-synuclein immunohistochemistry. Bars: 100 μm.
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tion led to a diagnosis of MSA-P.
Discussion
To the best of our knowledge, this is the first reported case
of a successful pregnancy in a woman with pathologically
proven MSA. Her pregnancy was complicated by objective
evidence of substantial neurological decline, which may
have been due to natural disease progression. However,
her clinical symptoms transiently improved shortly after
the delivery, suggesting a specific effect of pregnancy on
her symptoms. Similar observations have been reported in
pregnant women with PD [8,10]. The mechanism underly-
ing the increase of motor disability during pregnancy is
poorly understood. Pharmacokinetic variation of levodopa
caused by the volume and metabolic changes of pregnancy
could be a potential explanation. Other possible mechan-
isms include changes in hormone levels such as estrogen,
suggested by the positive and negative effect of estrogen
on central dopaminergic activity [11,12]. Pregnancy can
exacerbate orthostatic hypotension, even in the setting of
normal autonomic function, due to the expansion of circu-
latory system volume.
Most medications used for PD and orthostatic hypo-
tension are considered pregnancy category C based on
animal data but lack of adequate human evidence of tera-
togenicity [10]. Levodopa/carbidopa is generally consid-
ered to be safe in pregnancy given multiple successful
case reports of healthy deliveries in women with PD [10].
Our patient used only levodopa and carbidopa during her
pregnancy to avoid less studied effects of dopamine ago-
nists on fetal development. A relationship between the
use of levodopa-carbidopa and strabismus or dermoid
cyst has never been reported and is unknown.
The early stage of MSA can be difficult to distinguish
from Parkinson’s disease [4]. Our case confirms that DBS
is largely ineffective in MSA, as previously reported [13].
Future studies to develop early diagnostic biomarkers to
distinguish MSA from PD are crucial. Sporadic, early-
onset PD cases often have homozygous Parkin mutations
[14]. Although our patient has no family history of PD or
MSA, we speculate that genetic factors may have influ-
enced the onset of MSA at an unusual early age. Genome-
wide association studies of patients with MSA have found
genetic variants within the SNCA locus are associated
with increased risk for development of MSA [15]. Further
study will be needed to confirm if mutant a-synuclein was
responsible for our patient’s early-onset disease.
Conclusions
MSA can affect women of childbearing age and preg-
nancy may be associated with marked disease
progression.
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